ロード中...
Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
BACKGROUND: Bezlotoxumab is approved for prevention of recurrence of Clostridioides difficile infection (CDI) in adults receiving standard of care (SoC) therapy based on findings from MODIFY clinical trials. However, utilization practices and validation of trial results in the real world are limited...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7186524/ https://ncbi.nlm.nih.gov/pubmed/32363211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa097 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|